Charles River Laboratories Acquires SAMDI Tech

Charles River Laboratories acquired the remaining 80% stake in SAMDI Tech for $50 million in cash, completing a transaction that follows a partnership begun in 2018. The acquisition integrates SAMDI Tech's proprietary mass spectrometry high-throughput screening technology into Charles River's Discovery and Safety Assessment segment to strengthen drug discovery capabilities and accelerate hit identification for pharmaceutical and biotech clients.